Literature DB >> 1675557

Adjuncts to thrombolysis for myocardial reperfusion.

J J Popma1, E J Topol.   

Abstract

OBJECTIVE: To discuss adjunctive pharmacologic agents for acute myocardial infarction, to critique their initial effects in clinical trials, and to review their potential for improving the clinical conditions of patients with acute myocardial infarction. DATA SOURCES: Relevant studies reported from January 1985 to December 1990 were identified through a MEDLINE search of the English-language literature and through a manual search of the bibliographies of all identified articles. STUDY SELECTION: Peer-reviewed experimental and clinical studies evaluating the role of pharmacologic adjuncts to thrombolytic therapy in experimental models of coronary occlusion and clinical trials of patients with acute myocardial infarction were selected for review. DATA EXTRACTION AND SYNTHESIS: The data presented were abstracted by the investigators. Differences with a univariate P value of less than 0.05 were considered to be statistically significant.
CONCLUSIONS: Current clinical data suggest that adjunctive pharmacologic therapy to thrombolytic agents should include aspirin, at least 160 mg administered as soon as possible after the onset of symptoms; intravenous heparin; and, in selected patients without contraindications, intravenous beta-blockading agents.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1675557     DOI: 10.7326/0003-4819-115-1-34

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  5 in total

1.  Lethal "Reperfusion Injury": Is It a Real Entity?

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997-01       Impact factor: 2.300

2.  Enhancement of fibrinolysis in vitro by ultrasound.

Authors:  C W Francis; P T Onundarson; E L Carstensen; A Blinc; R S Meltzer; K Schwarz; V J Marder
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

Review 3.  New anticoagulant strategies. Current status and future potential.

Authors:  J Weitz
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

Review 4.  Thrombolytic therapy in acute myocardial infarction--selected recent developments.

Authors:  C Bode; T K Nordt; M S Runge
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

5.  Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.

Authors:  U Martin; L Dörge; S Fischer
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.